Ovation Science Inc. (CNSX: OVAT)
Health Care · Pharmaceuticals · CA
CA$—
— today · — 1Y
Ovation Science Inc. (CNSX: OVAT) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $822.39K and employs 5 people.
trading between 0.02 and 0.05.
Tweenvest scores Ovation Science Inc. across four factors: quality 9/100, value 46/100, growth 0/100. Its strongest factor is value.
OVAT price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $822.39K
- Revenue (TTM)
- $40.38K
- P/E
- —
- EPS
- -0.02
- Dividend yield
- —
- Beta (5Y)
- 0.72
- 52-week high
- CA$0.05
- 52-week low
- CA$0.02
- Avg volume (3M)
- —
- Shares outstanding
- 38.41M
- Employees
- 5
- Next earnings
- —
About Ovation Science Inc.
Ovation Science Inc. specializes in the creation of cannabis and hemp-based products, distributed across Canada, the United States, and Mexico. A cornerstone of its offerings is Invisicare, a patented drug delivery technology employed in topical and transdermal skincare formulations. This system integrates hemp seed oil and cannabis, underpinning the company's Ovation and BASKiN brands. Additionally, Ovation Science provides a diverse product portfolio including Invibe MD for CBD-infused health and wellness, ARLO CBD for skincare, and DermSafe for hand sanitizers. The company possesses sublicenses for its cannabis product lines and utilizes its Lighthouse initiative to engage with licensed dispensaries throughout the United States. Founded in 2017, Ovation Science Inc. is based in Vancouver, Canada.
- ISIN
- CA69016D1087
- Founded
- 2017
- Listed since
- Nov 16, 2018
- Exchange
- Canadian National Stock Exchange
- Currency
- CAD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.10T | $1,189.41 | -3.59% |
| Johnson & JohnsonNYSE: JNJ | $650.67B | $270.00 | -1.15% |
| Merck & Co., Inc.NYSE: MRK | $385.99B | $153.10 | -2.14% |
| Roche Holding AGSWX: ROP | $371.62B | CHF368.30 | -1.47% |
| Novartis AGSWX: NOVN | $303.81B | CHF128.34 | +1.25% |
| AstraZeneca PLCLSE: AZN | $263.84B | £122.34 | -1.94% |
| Novo Nordisk A/SCPSE: NOVO B | $212.51B | Dkr307.80 | +2.86% |
| Pfizer Inc.NYSE: PFE | $161.30B | $28.30 | -0.95% |
Figures last refreshed Aug 18, 2026.